Phosphorylated tau interactome in the human Alzheimer's disease brain

Phosphorylated tau interactome in the human Alzheimer's disease brain
复制标题

DOI:
10.1093/brain/awaa223
复制
发表时间:
2020-09-01
期刊:
影响因子:
14.5
通讯作者:
Wisniewski, Thomas
Wisniewski, Thomas
中科院分区:
医学1区
文献类型:
--
作者:
Drummond, Eleanor;Pires, Geoffrey;Wisniewski, Thomas

文献摘要

被引文献

相似文献

磷酸化tau蛋白的积累是阿尔茨海默病的关键病理特征。磷酸化tau蛋白的积累导致突触损伤、神经元功能障碍和神经元缠结的形成。磷酸化tau蛋白的病理作用是由周围的神经元蛋白介导的;然而,对磷酸化tau蛋白在阿尔茨海默病中相互作用的蛋白质的全面理解令人惊讶地有限。因此,本研究的目的是确定磷酸化tau相互作用体。为此,我们使用了两种互补的蛋白质组学方法:(i)对晚期阿尔茨海默病患者显微解剖的神经元缠结进行定量蛋白质组学研究;(ii)亲和纯化-质谱法用于鉴定哪些蛋白质特异性结合磷酸化tau蛋白。我们在神经元缠结中鉴定了542种蛋白质。这包括大量检测到许多已知存在于神经元缠结中的蛋白质,如tau蛋白、泛素、神经丝蛋白和载脂蛋白E。亲和纯化-质谱法证实,75个蛋白质存在于神经元缠结与PHF 1-免疫反应性磷酸化tau相互作用。这些蛋白质中有29种以前与磷酸化tau蛋白相关,因此验证了我们的蛋白质组学方法。更重要的是,34种蛋白质先前与总tau蛋白相关,但尚未与磷酸化tau蛋白直接相关(例如突触蛋白VAMP 2,空泡ATP酶亚基ATP 6V 0 D1);因此,我们提供了新的证据,表明它们直接与阿尔茨海默病中的磷酸化tau蛋白相互作用。此外,我们还鉴定了12种新的蛋白质,以前不知道与tau蛋白(例如RNA结合蛋白HNRNPA 1)在生理学或病理学上相关。网络分析表明,磷酸化的tau蛋白相互作用体富含参与蛋白泛素化途径和吞噬体成熟的蛋白质。重要的是,我们能够首次确定磷酸化tau在这些途径中相互作用的特定蛋白质,因此提供了可以在未来研究中探索的新的潜在致病机制。结合起来,我们的研究结果揭示了治疗tau蛋白病的新的潜在药物靶点,并提供了对磷酸化tau蛋白如何介导其在阿尔茨海默病中的毒性的见解。
Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease. Phosphorylated tau accumulation causes synaptic impairment, neuronal dysfunction and formation of neurofibrillary tangles. The pathological actions of phosphorylated tau are mediated by surrounding neuronal proteins; however, a comprehensive understanding of the proteins that phosphorylated tau interacts with in Alzheimer's disease is surprisingly limited. Therefore, the aim of this study was to determine the phosphorylated tau interactome. To this end, we used two complementary proteomics approaches: (i) quantitative proteomics was performed on neurofibrillary tangles microdissected from patients with advanced Alzheimer's disease; and (ii) affinity purification-mass spectrometry was used to identify which of these proteins specifically bound to phosphorylated tau. We identified 542 proteins in neurofibrillary tangles. This included the abundant detection of many proteins known to be present in neurofibrillary tangles such as tau, ubiquitin, neurofilament proteins and apolipoprotein E. Affinity purification-mass spectrometry confirmed that 75 proteins present in neurofibrillary tangles interacted with PHF1-immunoreactive phosphorylated tau. Twenty-nine of these proteins have been previously associated with phosphorylated tau, therefore validating our proteomic approach. More importantly, 34 proteins had previously been associated with total tau, but not yet linked directly to phosphorylated tau (e.g. synaptic protein VAMP2, vacuolar-ATPase subunit ATP6V0D1); therefore, we provide new evidence that they directly interact with phosphorylated tau in Alzheimer's disease. In addition, we also identified 12 novel proteins, not previously known to be physiologically or pathologically associated with tau (e.g. RNA binding protein HNRNPA1). Network analysis showed that the phosphorylated tau interactome was enriched in proteins involved in the protein ubiquitination pathway and phagosome maturation. Importantly, we were able to pinpoint specific proteins that phosphorylated tau interacts with in these pathways for the first time, therefore providing novel potential pathogenic mechanisms that can be explored in future studies. Combined, our results reveal new potential drug targets for the treatment of tauopathies and provide insight into how phosphorylated tau mediates its toxicity in Alzheimer's disease.